REGENERON PHARMACEUTICALS, INC.: FDA Accepts for Priority Review Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
If approved, Dupixent would be the first biologic medicine available in the U.S. for these children